Skip to main content

Breast Cancer Research and Treatment

Ausgabe 1/2023

Inhalt (21 Artikel)

Open Access Review

Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis

Nanna Jordt, Kasper Aalbæk Kjærgaard, Reimar W. Thomsen, Signe Borgquist, Deirdre Cronin-Fenton

Preclinical study

Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study

Libo Yang, Heather Lin, Yu Shen, Madhuchhanda Roy, Constance Albarracin, Qingqing Ding, Lei Huo, Hui Chen, Bing Wei, Hong Bu, Isabelle Bedrosian, Yun Wu

Open Access Preclinical study

Numerical and physical modeling of breast cancer based on image fusion and artificial intelligence

Bartosz Dołęga-Kozierowski, Piotr Kasprzak, Michał Lis, Bartłomiej Szynglarewicz, Rafał Matkowski, Marek Sawicki, Mateusz Dymek, Adrianna Szumiejko, Gustavo Carmo, Artur Kwiatkowski, Daniel Grzegorz Soliński, Mariusz Ptak

Open Access Preclinical study

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study

Lin Sui, Yuqi Yan, Tian Jiang, Di Ou, Chen Chen, Min Lai, Chen Ni, Xi Zhu, Liping Wang, Chen Yang, Wei Li, Jincao Yao, Dong Xu

Open Access Clinical Trial

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial

Cristiano de Pádua Souza, Ana Suellen Barroso Carneiro, Ana Cecília de Oliveira Lessa, Domício Carvalho Lacerda, Carlos Eduardo Paiva, Marina Moreira Costa Zorzetto, Ana Julia Aguiar de Freitas, Iara Viana Vidigal Santana, Marco Antonio de Oliveira, Edenir Inêz Palmero, Márcia Maria Chiquitelli Marques, Tomás Reinert

Open Access Clinical trial

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial

Léa L. Volmer, Dominik Dannehl, Tobias Engler, Markus Hahn, Christina B. Walter, Markus Wallwiener, Sara Y. Brucker, Florin-Andrei Taran, Andreas D. Hartkopf

Open Access Clinical trial

Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer

Matthew G. Davey, Ray Abbas, Eoin P. Kerin, Maire Caitlin Casey, Andrew McGuire, Ronan M. Waldron, Helen M. Heneghan, John Newell, Ailbhe M. McDermott, Maccon M. Keane, Aoife J. Lowery, Nicola Miller, Michael J. Kerin

Open Access Clinical trial

High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors

Alv A. Dahl, Solveig K. Smedsland, Kathrine F. Vandraas, Synne K. Bøhn, Ragnhild S. Falk, Cecilie E. Kiserud, Kristin V. Reinertsen

Open Access Epidemiology

COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019–2021

Judith A. Malmgren, Boya Guo, Mary K. Atwood, Paula Hallam, Laura A. Roberts, Henry G. Kaplan

Epidemiology

Increases in BMI contribute to worsening inflammatory biomarkers related to breast cancer risk in women: a longitudinal study

Yu Hao, Jinyu Xiao, Ping Fu, Lanping Yan, Xunying Zhao, Xueyao Wu, Min Zhou, Xiaofan Zhang, Bin Xu, Xingyue Li, Zhenmi Liu, Chunxia Yang, Xin Wang, Lu Long, Xia Jiang, Jiaqiang Liao, Ben Zhang, Jiayuan Li

Epidemiology

The impact of nurse navigation on timeliness to treatment for benign high-risk breast pathology

Catherine S. Barker, Catherine W. Chung, Rupak Mukherjee, Julie B. Siegel, David J. Cole, Mark A. Lockett, Nancy Klauber-DeMore, Andrea M. Abbott

Open Access Epidemiology

Effect of neighborhood deprivation index on breast cancer survival in the United States

Arya Mariam Roy, Anthony George, Kristopher Attwood, Sabah Alaklabi, Archit Patel, Angela R. Omilian, Song Yao, Shipra Gandhi

Open Access Epidemiology

Factors associated with insomnia symptoms over three years among premenopausal women with breast cancer

Chloe M. Beverly Hery, Sarah A. Janse, Kimberly J. Van Zee, Elizabeth Z. Naftalis, Electra D. Paskett, Michelle J. Naughton

Open Access Brief Communication

Changes in the incidence of early-onset breast cancer in Germany between 2010 and 2022

Niklas Gremke, Uwe Wagner, Matthias Kalder, Karel Kostev

Original Laboratory Investigation

Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients

Fengling Li, Hong Chen, Xunxi Lu, Yani Wei, Yuanyuan Zhao, Jing Fu, Xiuli Xiao, Hong Bu

Open Access Original Laboratory Investigation

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S. Cogan, Vandana G. Abramson, Judy C. Boughey, Carla Falkson, Matthew P. Goetz, James M. Ford, William J. Gradishar, Rachel C. Jankowitz, Virginia G. Kaklamani, P. Kelly Marcom, Andrea L. Richardson, Anna Maria Storniolo, Nadine M. Tung, Shaveta Vinayak, Darren R. Hodgson, Zhongwu Lai, Simon Dearden, Bryan T. Hennessy, Erica L. Mayer, Gordon B. Mills, Thomas P. Slavin, Alexander Gutin, Roisin M. Connolly, Melinda L. Telli, Vered Stearns, Jerry S. Lanchbury, Kirsten M. Timms

Original Laboratory Investigation

Effects of neighborhood disadvantage on cortisol and interviewer-rated anxiety symptoms in breast cancer patients initiating treatment

Neha Goel, Alexandra E Hernandez, Molly Ream, Estefany Saez Clarke, Bonnie B. Blomberg, Steve Cole, Michael H. Antoni

Retraction Note

Retraction Note: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways

C. Buchanan, I. Stigliano, H. M. Garay-Malpartida, L. Rodrigues Gomes, L. Puricelli, M. C. Sogayar, E. Bal de Kier Joffe, M. G. Peters

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.